Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FiO2 Thresholds for Surfactant in Preterm RDS
NCT04199364Phase 4Unknown
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, single-blind trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms). Primary endpoint: Respiratory pulmonary function at Day 3. Status: unknown.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT04199364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199364.